Lifeline Biotechnologies, Inc. Expects to Upgrade Capabilities of Its First Warning System(TM) in 2008

RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (OTCPK:LLBT) today announced the Company expects to make meaningful progress in the upgrading of its First Warning System™ (FWS) computer software analytical and interpretive system (CSAIS). Lifeline has set specifications for the engineers at Nanyang Technical University (NTU) to upgrade the software so it is more sensitive.

The CSAIS, based on neural net technology, categorizes patient data into one of three classifications: normal, suspicious and abnormal physiology which could indicate the presence of breast cancer. As previously reported, the engineers at NTU are focused on processing the patient data recently provided to them by the Company in order to increase the software's ability to recognize and categorize patient data into these three classifications.

“The CSAIS is a neural net technology, trained to identify cancer. We have set specifications for the NTU engineers, and the recent reports from our engineers indicate that we are making meaningful progress toward meeting these specifications and look forward to the prospect of potentially accomplishing them in 2008,” stated Jim Holmes, CEO of Lifeline Biotechnologies, Inc.

Lifeline recently announced that the Company has been in discussions with various firms to prepare filing the 510(k) with the FDA. The selected firm will help with the verification and validation guidelines, and the Company expects to announce its selection soon.

About Lifeline Biotechnologies, Inc:

Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which was designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed: the development of the First Warning System™, the completion of clinical trials and FDA pre-marketing clearance. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. Additional information is at the Company’s website: www.lbti.com. The website is being updated.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:

Lifeline Biotechnologies, Inc.
Investor Relations 
866-284-2835
www.lbti.com 

Source: Lifeline Biotechnologies, Inc.